Ventrus Biosciences Stock Price (NASDAQ:ASMB)

Add to My Stocks
$58.54 $1.13 (1.89%) ASMB stock closing price Mar 19, 2018 (Closing)
Prev Close* : $59.67
Market Cap:
Day Low: $57.37
52 Week Low: $18.60
Open: $59.25
Volume: -
Day High: $60.7
52 Week High: $67.36

Latest Stock Market News

Latest Articles

Ventrus Biosciences News - From Partners

Assembly Biosciences Announces 2017 AASLD Presentations   by Globe Newswire on Oct 02, 2017

ASMB Stockcharts

View ASMB PE ratio, PS ratio stocks charts and compare with peers.
ASMB Chart
Note: Compare Ventrus Biosciences stock price history with the index and industry peers.

Ventrus Biosciences Valuation

PE ratio
(price earnings ratio)
PS ratio (
price to sales ratio
PB ratio (
price to book ratio

Ventrus Biosciences Returns

(return on equity)

Ventrus Biosciences Financial Ratios

Asset Turnover
Receivables Turnover
Debt to Equity
Dividend Yield

ASMB Industry Peers

Company Price Change (%)
Mallinckrodt (MNK)15.20.89 (5.53%)
Celator Pharma (CPXX)30.240 (0%)
Cytodyn (CYDY)0.690 (0%)
Paratek Pharma (PRTK)13.850.55 (3.82%)
Chimerix (CMRX)5.570.07 (1.24%)
Anacor Pharma (ANAC)99.20 (0%)
Newlink Genetics (NLNK)6.930.31 (4.28%)

Top Stock Gainers

show top losers
CompanyPriceChange (%)
Teligent (TLGT)3.160.16 (5.33%)
AxoGen (AXGN)37.850.2 (0.53%)
Top gainers from Medical-Generic Drugs industry
* As of Mar 20, 2018
CompanyPriceChange (%)
Mallinckrodt (MNK)15.20.89 (5.53%)
Adamas Pharma (ADMS)26.091.01 (3.73%)
Agile Therapeutics (AGRX)2.920.11 (3.63%)
AEVI GENOMIC (GNMX)1.970.07 (3.43%)
Impax Lab (IPXL)20.450.6 (2.85%)
Teva Pharmaceutical (TEVA)17.910.46 (2.5%)
Mylan (MYL)40.80.93 (2.23%)
Top losers from Medical-Generic Drugs industry
* As of Mar 20, 2018

Assembly Biosciences Inc Stock News - Partner Headlines

Ventrus Biosciences Financial Statements

income statement20162015201420132012
Net Sales or Revenues-----
Net Income-44.26M-28.45M-23.78M-19.4M-24.79M
Total Operating Expense45.27M29.64M23.94M19.59M24.85M
View Ventrus Biosciences income statement
balance sheet20162015201420132012
Total Assets98.11M133.74M71.22M27.13M20.55M
Total Liabilities18.24M15M12.65M2.63M2.74M
Shareholders Equity79.87M118.74M58.57M24.49M17.81M
View Ventrus Biosciences balance sheet
cash flow statement20162015201420132012
Net Increase (Decrease) in Assets Liabilities3.75M1.78M-2.51M-0.11M-
Net Cash from (used by) Operating Activities-34.88M-18.69M-14.97M-17.79M-21.37M
Increase (Decrease) in Prop Plant And Equipment-0.14M-0.05M-0.14M-0.01M-
View Ventrus Biosciences cash flow statement

Ventrus Biosciences Stock Message Board

Ventrus Biosciences stock price ended the last trading day at $58.54. Looking at Ventrus Biosciences market capitalization, which currently stands at $1.21B, we can say that ASMB stock is a Small Cap stock. A value investor must look at the fundamentals of a stock, and perform Ventrus Biosciences valuation, even though in the short-term, sentiment and current breaking news might affect Ventrus Biosciences stock price.

For recognizing and analyzing the real performance of Ventrus Biosciences stock, it is a standard practise to adjust historical stock prices to remove gaps caused by stock splits, dividends and distributions. The volume of shares traded stood at 143,358 on the last trading day, as is evident from Ventrus Biosciences stock chart, and ASMB stock quote data. Dividends are usually paid by large stable companies, and typically not by those which are in their rapid growth stages. A company's continuing success is indicated by a steadily increasing dividend payout. Ventrus Biosciences dividend per share was 0.00 during the last quarter. To check the historical stock price movement, all time high, and all time low of ASMB, view Ventrus Biosciences stock price history.